GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Termedia Sp. z.o.o.  (2)
  • Falsetti, Paolo  (2)
Material
Publisher
  • Termedia Sp. z.o.o.  (2)
Person/Organisation
Language
Years
  • 1
    Online Resource
    Online Resource
    Low muscle mass and body composition analysis in a group of postmenopausal women affected by primary Sjögren’s syndrome
    Termedia Sp. z.o.o. ; 2021
    In:  Rheumatology Vol. 59, No. 3 ( 2021-7-16), p. 153-160
    Details
    In: Rheumatology, Termedia Sp. z.o.o., Vol. 59, No. 3 ( 2021-7-16), p. 153-160
    Abstract: Sarcopenia is the pathological reduction of skeletal muscle mass and strength. This condition is often underestimated in clinical practice, particularly in connective tissue diseases. The purpose of this study is to evaluate the prevalence of low muscle mass in primary Sjögren’s syndrome (pSS) and to explore the relationships linking muscles and bone tissue. Material and methods Twenty-eight postmenopausal pSS patients were matched with 30 healthy controls and their body composition analysis was performed by dual-energy X-ray absorptiometry to investigate for sarcopenia considering appendicular lean mass (ALM) and the skeletal muscle mass index (SMI) as references. Bone mineral density analysis of lumbar spine (L1–L4), whole femur, femoral neck and whole body was also performed. Linear regression was used to assess the relationship between body composition and bone mineralization. Results Low muscle mass was significantly higher in the pSS group compared to controls whether expressed as ALM, SMI [odds ratio (OR) = 18.40, confidence interval (CI): 4.84–72.08, p 〈 0.0001] or considering total body lean masses. Lean masses appeared to be the best estimators of bone mineralization: total lean body mass (TLBM) lumbar spine R2 = 0.72, p 〈 0.0001; TLBM femoral neck R2 = 0.36, p 〈 0.004; lean mass of upper limbs lumbar spine R2 = 0.70, p 〈 0.0001; femoral neck R2 = 0.66; lean mass of lower limbs lumbar spine R2 = 0.66, p 〈 0.0001; femoral neck R2 = 0.44, p = 0.008). Primary Sjögren’s syndrome patients had a significantly higher android/gynoid fat ratio compared to controls. Conclusions Female pSS patients have lower muscle mass compared to healthy controls and are exposed to a higher risk of developing sarcopenia than healthy subjects. Our research demonstrates that the amount of lean tissue is the main predictor of bone mineralization in pSS.
    Type of Medium: Online Resource
    ISSN: 0034-6233 , 2084-9834
    URL: Article
    DOI: 10.5114/reum.2021.106909
    Language: Unknown
    Publisher: Termedia Sp. z.o.o.
    Publication Date: 2021
    detail.hit.zdb_id: 2233668-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Bone-sparing effects of rituximab and body composition analysis in a cohort of postmenopausal women affected by rheumatoid arthritis – retrospective study
    Termedia Sp. z.o.o. ; 2021
    In:  Rheumatology Vol. 59, No. 4 ( 2021-9-2), p. 206-210
    Details
    In: Rheumatology, Termedia Sp. z.o.o., Vol. 59, No. 4 ( 2021-9-2), p. 206-210
    Abstract: Osteoporosis is the most common bone tissue disease and it is characterized by a re�duced bone mineral density (BMD). The main physiopathological mechanisms converge on the un�coupling between bone formation and resorption, thus leading to an enhanced risk of fractures. Several papers have documented the inverse relationships linking high inflammatory cytokines, anti�citrullinated protein antibodies, rheumatoid factor, and BMD in rheumatoid arthritis (RA). Rituximab (RTX) is a chimeric monoclonal antibody directed against the CD20 receptor of B cells. Since the Food and Drug Administration approved it for RA in 2006, there have been many clinical experiences regarding its use. Nevertheless, few studies evaluate the effect of rituximab on BMD. RA is a disease characterized by immune dysfunction with high levels of inflammatory cytokines, autoantibodies, and it is reasonable that a B cell depleting therapy could restore a physiological cytokine balance, thus exerting an osteoprotective effect on the bone tissue. The purpose of this paper is to highlight any difference in BMD and to assess differences in body composition over a retrospective 18-month follow-up period after RTX treatment with a B cell depleting therapy. Material and methods We analyzed by dual energy X-ray absorptiometry BMD expressed as g/cm2 and body composition modifications over 18 months with RTX treatment of 20 postmenopausal RA patients. Results After eighteen months of therapy with RTX, a statistically significant increase in vertebral (L1–L4) BMD and the stability of femoral BMD were documented. Conclusions Rituximab is associated with an improvement of vertebral and preservation of femo�ral BMD, suggesting a bone-sparing effect due to B cell depletion. Furthermore, patients displayed a redistribution of fat masses toward the hip region.
    Type of Medium: Online Resource
    ISSN: 0034-6233 , 2084-9834
    URL: Article
    DOI: 10.5114/reum.2021.108430
    Language: Unknown
    Publisher: Termedia Sp. z.o.o.
    Publication Date: 2021
    detail.hit.zdb_id: 2233668-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...